Centauri Therapeutics
To add a bio or update company history, please click update information.
News from Centauri Therapeutics
Centauri Therapeutics
24 Feb 2026
Centauri Therapeutics secures a £6m Series A extension from AMR Action Fund to target drug-resistant bacterial infections with immunotherapy
Centauri Therapeutics is a biotechnology startup developing immunotherapies using its Alphamer platform. Its treatments are designed to harness the body’s immune response to target infectious diseases, including multidrug-resistant bacteria.
Centauri Therapeutics
29 Jul 2025
Centauri Therapeutics secures a further £3.8m from CARB-X to advance antimicrobial candidate into clinical trials
Centauri Therapeutics develops antimicrobial therapies based on a proprietary immunotherapy platform, with its lead candidate designed to treat serious drug resistant bacterial infections of the lung.
Centauri Therapeutics
- Life Sciences
- Cheshire, United Kingdom
- £9.8m
- centauritherapeutics.com
- Update Information
More venture news
- 23 Sept 2026
Basecamp ResearchBasecamp Research unlocks £105m Series C led by S32 to design medicines with frontier AI models
Series CLife Sciences - 18 Sept 2026
Big Picture BioBig Picture Bio raises a £1.5m pre-seed round led by Kadmos Capital and Exceptional Ventures to design cancer combination therapies
Pre-seedLife Sciences - 16 Sept 2026
Eterna RegenerativesEterna Regeneratives closes a seed round led by Hoxton Ventures and The Venture Collective to develop keratin-based enamel repair
SeedLife Sciences
